PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
August 18, 2026The BreastOpen Access

Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial

View Full Paper
Ask AI
Bookmark
Share

Authors

TDTejal D. DurgekarSGShyamili GouthamXZXi Zhang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Durgekar et al. (2026) studied this question.

synapsesocial.com/papers/6aa6b38fe8c87b1c7e396a0dhttps://doi.org/10.1016/j.breast.2026.104903
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.2024 · 13 citations
  2. 2Breast Cancer Version 3.20142014 · 185 citations
  3. 3Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy2020 · 138 citations